Pharmaceuticals, Biotechnology and Life Sciences
LabCorp joins QIAGEN’s “Day-One” program designed to help deliver precision medicine to patients faster HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)—-QIAGEN…
Bristol-Myers Squibb and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment.
Cellectis’s scinetists lead by Dr Alexandre Juillerat have designed a new CAR architecture that contains an integrated microenvironment sensor. Their work was recently published in a scientific magazine “Scientific Reports”.